Recruiting
Phase 3

ECUR-506

Sponsor:

iECURE, Inc.

Code:

NCT06255782

Conditions

Ornithine Transcarbamylase Deficiency

Ornithine Transcarbamylase Deficiency Disease

Ornithine Carbamoyltransferase Deficiency (Disorder)

Urea Cycle Disorders, Inborn

Eligibility Criteria

Sex: Male

Age: 0

Healthy Volunteers: Not accepted

Interventions

ECUR-506

Study Details

Brief summary:

Ornithine Transcarbamylase (OTC) deficiency, the most common urea cycle disorder, is an inherited metabolic disorder caused by a genetic defect in a liver enzyme responsible for detoxifying of ammonia. Individuals with OTC deficiency can develop elevated levels of ammonia in the blood, potentially resulting in severe consequences, including cumulative and irreversible neurological damage, coma, and death. The most severe form presents shortly after birth and occurs more commonly in boys than girls.

This is a Phase 1/2/3, open-label, multicenter study evaluating the safety, efficacy, and dose of ECUR-506 in male babies with neonatal-onset OTC deficiency. The primary objective is to evaluate the safety, tolerability, and efficacy of up to three dose levels of ECUR-506 following intravenous (IV) administration of a single dose.

Conditions

Ornithine Transcarbamylase Deficiency

Ornithine Transcarbamylase Deficiency Disease

Ornithine Carbamoyltransferase Deficiency (Disorder)

Urea Cycle Disorders, Inborn

Study ID

NCT06255782

Start date

Apr 8, 2024

Status verified date

Aug, 2026

Completion date

Dec, 2027

Anticipated

Primary completion date

Dec, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Male

Age: 0

Healthy Volunteers: Not accepted

Key Inclusion Criteria:

1. Male sex
2. Gestational or adjusted (corrected) gestational age ≥ 37 weeks
3. Age at screening is 24 hours to 7 months
4. Weight ≥ 3.5 kg and ≤ 13.5 kg at screening
5. Has received age-appropriate vaccinations
6. Genetically confirmed OTCD defined by genetic confirmation of an OTC variant (pathogenic or likely pathogenic) associated with severe neonatal OTCD defined below in Inclusion Criteria #7 or has the same OTC variant as a family member who had severe neonatal OTCD within first week of life.
7. Severe neonatal OTCD defined by hyperammonemic crisis with elevated ammonia level of >560 μmol/L and clinical symptoms within first week of life, and currently receiving treatment with both dietary protein restriction and nitrogen scavenger therapy.
8. Current or historical biochemical profile consistent with OTCD
9. Participant's parent(s)/LAR must be able to comprehend and be willing to provide a signed IRB/IEC-approved ICF.

Key Exclusion Criteria:

1. Neonatal diagnosis of severe to profound Hypoxic Ischemic Encephalopathy due to birth injury
2. Requiring urgent liver transplant due to liver failure as assessed by the PI.
3. Contiguous gene deletion involving the OTC gene and including at least the CYBB gene on the telomeric side or the TSPAN7 gene on the centromeric side.
4. Known or suspected major organ injury/dysfunction/anomalies.
5. Vital sign and laboratory abnormalities outside of reference ranges.
6. Treatment with any other gene therapy or gene editing therapy
7. Co-enrollment in any other study unless approved by the sponsor.
8. Any condition, that in the opinion of the Investigator, would compromise the safety of the participant or study data
9. Documented vertical transmission of HepA/HepB/HepC
10. Documented in-utero teratogen, substance, and/or alcohol exposure, which in the opinion of the Investigator may increase the participant's risk of developmental delays, congenital anomalies, and/or significant medical complications

Study Design

Enrollment

20 participants

Anticipated

Allocation

Non randomized

Intervention Model

Sequential

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Low Dose Level

Participants will receive the Low Dose of ECUR-506 delivered one time via IV Infusion.

experimental: Intermediate Dose Level

Participants will receive an intermediate dose of ECUR-506 delivered on time via IV infusion

experimental: High Dose Level

Participants will receive a higher dose of ECUR-506 delivered one time via IV infusion.

Interventions

ECUR-506

ECUR-506 is a gene editing treatment delivering a gene encoding the editing enzyme and an OTC gene.

Primary outcome measure

  • Treatment-emergent adverse events (incidence, severity, seriousness, and relatedness) [ Time Frame: Over 24 weeks post infusion ]
  • Physical exam parameters [ Time Frame: Assessed as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants. ]
  • Vital sign parameters [ Time Frame: Assessed as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants. ]
  • Pediatric neurologist exam parameters [ Time Frame: Assessed as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants. ]
  • Blood safety tests including hematology, serum chemistry, liver function tests, coagulation tests [ Time Frame: as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants. ]
  • Urinalysis evaluations [ Time Frame: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion. ]
  • 12 lead ECG parameters [ Time Frame: as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants. ]
  • Complete clinical response [ Time Frame: Over 24 weeks post infusion ]

Central Contacts and Locations

Central contacts

George Diaz, M.D., Ph.D.

1-877-694-3558medinfo@iecure.com

Trial Recruitment

clinicaltrials@iecure.com

Locations

UCLA Mattel Children's Hospital

Recruiting

Los Angeles, California, United States, 90095

Contacts

Children's Hospital of Colorado, Anshutz Medical Campus

Recruiting

Aurora, Colorado, United States, 80045

Contacts

Emory University School of Medicine

Recruiting

Atlanta, Georgia, United States, 30322

Contacts

Eleanor Geller Botha

egeller@emory.edu

Ann & Robert H. Lurie Children's Hospital of Chicago

Recruiting

Chicago, Illinois, United States, 60611

Contacts

Icahn School of Medicine at Mount Sinai

Recruiting

New York, New York, United States, 10029

Contacts

Oregon Health and Science University

Recruiting

Portland, Oregon, United States, 97239

Contacts

Hadley Morotti, MS

morotti@ohsu.edu

More Information

Sponsor

iECURE, Inc.

Last update posted

Aug 12, 2026

Last verified

Aug, 2026

Keywords

  • Amino Acid Metabolism, Inborn Errors
  • Ammonia
  • Brain Diseases
  • Brain Diseases, Metabolic
  • Brain Diseases, Metabolic, Inborn
  • Central Nervous System Diseases
  • Genetic Diseases, Inborn
  • Genetic Diseases, X-Linked
  • High Ammonia
  • Hyperammonemia
  • Inborn
  • Inborn Errors
  • Inherited Metabolic Disorders
  • Liver Disease
  • Liver Transplant
  • Metabolism
  • Metabolic Diseases
  • Metabolism, Inborn Errors
  • Neonatal
  • Nervous System Diseases
  • Neurometabolic disorders
  • NH4
  • Ornithine
  • Ornithine Transcarbamylase Deficiency
  • OTC
  • OTC Deficiency
  • OTCD
  • Transcarbamylase
  • UCD
  • Urea Cycle Disorders
  • X-Linked

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by iECURE, Inc. on 2026-08-12.